ATE349531T1 - Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendung - Google Patents

Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendung

Info

Publication number
ATE349531T1
ATE349531T1 AT01928715T AT01928715T ATE349531T1 AT E349531 T1 ATE349531 T1 AT E349531T1 AT 01928715 T AT01928715 T AT 01928715T AT 01928715 T AT01928715 T AT 01928715T AT E349531 T1 ATE349531 T1 AT E349531T1
Authority
AT
Austria
Prior art keywords
csa operon
etec
pili
characterization
isolation
Prior art date
Application number
AT01928715T
Other languages
English (en)
Inventor
Zeev Altboum
Myron M Levine
Eileen M Barry
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of ATE349531T1 publication Critical patent/ATE349531T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT01928715T 2000-04-20 2001-04-20 Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendung ATE349531T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19862600P 2000-04-20 2000-04-20

Publications (1)

Publication Number Publication Date
ATE349531T1 true ATE349531T1 (de) 2007-01-15

Family

ID=32849273

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01928715T ATE349531T1 (de) 2000-04-20 2001-04-20 Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendung

Country Status (15)

Country Link
US (2) US6902736B2 (de)
EP (1) EP1280912B1 (de)
AT (1) ATE349531T1 (de)
AU (2) AU2001255543B2 (de)
CA (1) CA2407523A1 (de)
CZ (1) CZ20023795A3 (de)
DE (1) DE60125528T2 (de)
ES (1) ES2276785T3 (de)
HU (1) HUP0300297A3 (de)
MX (1) MXPA02010407A (de)
NO (1) NO20025146L (de)
NZ (1) NZ522272A (de)
PL (1) PL359293A1 (de)
WO (1) WO2001081582A2 (de)
ZA (1) ZA200209042B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1372708T3 (da) * 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
AU2002365374A1 (en) * 2001-11-28 2003-06-10 Angiogenetics Sweden Ab Regulation of hypoxia-inducible gene expression with antisense inhibitory pas domain protein
AU2003213233B2 (en) * 2002-02-25 2009-02-05 U.S. Army Medical Research And Materiel Command Method of making CS6 antigen vaccine for treating, preventing, or inhibiting enterotoxigenic escherichia coli infections
EP1855718B1 (de) * 2005-01-11 2016-10-12 The United States of America as represented by The Secretary of The Navy Donor Strang komplementierte Adhesine als immunogen gegen Escherichia coli.
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
EP2294090B1 (de) * 2008-06-03 2014-05-14 University of Maryland, Baltimore NICHT HÄMOLYTISCHES ClyA FÜR PROTEINAUSSCHEIDUNG
EP2897638A1 (de) 2012-09-24 2015-07-29 Montana State University-Bozeman Rekombinanter lactococcus lactis zur expression des escherichia coli-kolonisationsfaktor-antigens i (cfa/i) fimbriae und verfahren zu deren verwendung
AU2013345316B2 (en) 2012-11-19 2016-04-14 The United States Of America As Represented By The Secretary Of The Navy Recombinant polypeptide construct comprising multiple enterotoxigenic Escherichia coli fimbrial subunits
US9925254B2 (en) 2014-11-05 2018-03-27 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against Campylobacter jejuni
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
CN117051021B (zh) * 2023-08-01 2024-09-20 扬州大学 非诱导型表达鸡白痢沙门菌Bcf菌毛的鸡伤寒沙门菌重组菌及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5417986A (en) * 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE287703T1 (de) 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US5914114A (en) 1995-06-02 1999-06-22 The United States Of America As Represented By The Secretary Of The Army Method of raising antibodies against E. coli of the family CS4-CFA/I
US5932715A (en) * 1995-06-07 1999-08-03 Emory University Nucleotide sequences encoding a CS2 pilin protein
WO1997044446A1 (en) 1996-05-24 1997-11-27 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen

Also Published As

Publication number Publication date
HUP0300297A3 (en) 2005-09-28
NO20025146D0 (no) 2002-10-25
AU5554301A (en) 2001-11-07
EP1280912B1 (de) 2006-12-27
CA2407523A1 (en) 2001-11-01
NZ522272A (en) 2004-09-24
US20050136070A1 (en) 2005-06-23
US7399474B2 (en) 2008-07-15
WO2001081582A2 (en) 2001-11-01
AU2001255543B2 (en) 2005-06-23
DE60125528D1 (de) 2007-02-08
DE60125528T2 (de) 2007-10-11
US6902736B2 (en) 2005-06-07
PL359293A1 (en) 2004-08-23
CZ20023795A3 (cs) 2003-04-16
NO20025146L (no) 2002-12-05
ES2276785T3 (es) 2007-07-01
EP1280912A2 (de) 2003-02-05
HUP0300297A2 (en) 2003-05-28
US20020176868A1 (en) 2002-11-28
ZA200209042B (en) 2004-03-08
WO2001081582A3 (en) 2002-05-02
MXPA02010407A (es) 2003-05-23

Similar Documents

Publication Publication Date Title
DK1373296T3 (da) Proteiner, der frembringer et ændret immunogent respons, og fremgangsmåder til fremstilling og anvendelse deraf
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
WO2001034801A3 (en) Recombinant gelatin in vaccines
WO2004043407A3 (en) Methods and products for treating staphylococcal infections
WO1996034107A3 (en) Antiviral proteins, dna coding sequences therefor, and uses thereof
DE69929444D1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
NO20003958L (no) Tumor assosierte antigen derivater fra MAGE familien, og nuklein syre sekvenser som koder for disse, anvendt for fremstilling av fusjons proteiner og for vaksinesammensetninger
DE60125528D1 (de) Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendung
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
WO2004075829A3 (en) Adjuvanted influenza vaccine
WO2004026265A3 (en) Compositions and methods for treatment of herpesvirus infections
PL1675956T3 (pl) Minimalna sekwencja DNA działająca jako insulator chromatyny i jej zastosowanie do wyrażania białek
SG167667A1 (en) Nucleic acid compositions for stimulating immune responses
FR21C1005I2 (fr) Antigenes de streptococcus pyogenes et fragments d'adn correspondants
ATE541036T1 (de) Verfahren zur überexpression zwitterionischer polysaccharide
DK0892054T3 (da) Clostridium perfringens-vaccine
SG146662A1 (en) Method
PT1290160E (pt) Polipeptideos pellino humanos
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.
WO2007050095A3 (en) Improved vaccines and methods for using the same
ATE161049T1 (de) Verfahren und nukleinsäuresequenzen zur expression des zellulose-synthase-operons
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
DK0811068T3 (da) Humane DNase I varianter

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties